A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants

Inclusion Criteria:

1. Healthy males or females aged 18 through 50 years
2. Male subjects with a weight of ≥50 kg, female subjects with a weight of ≥45 kg, andBMI between 19.0 and 26.0 kg/m² (inclusive).
3. Vaccination: Meningococcal Conjugate Vaccine, Serogroups A, C, W, Y (MPV-ACYW)meningococcal conjugate vaccine and Streptococcus pneumoniae vaccine should be given 14 days or more before randomisation.
4. Male subjects and their partners or female subjects must agree to use one or morenon-pharmaceutical contraceptive methods (such as total abstinence, condoms, Iuds,partner ligation, etc.) during the trial period and for 6 months after the trial, anddo not plan to donate sperm or eggs.
5. The subjects fully understand the purpose, nature, method and possible adversereactions of the experiment, and voluntarily participate in the experiment and signthe informed consent.
6. The subjects were able to communicate well with the researchers and complete the studyaccording to the protocol.

Exclusion Criteria:

1. Participants who are immunocompromised or have one of the following underlyingdiseases: anatomic absence of spleen (including sickle cell disease); congenitalcomplement component deficiencies (complement component 3 and complement component 4).
2. Any history of Neisseria gonorrhea, meningitis infection, and Guillain-Barré syndrome.
3. Contraindications to meningococcal vaccination (previous medical history such asepilepsy or other brain disorders).
4. Presence or suspicion of active viral, bacterial, fungal, or parasitic infection,including herpes, shingles, or cold sores, within 14 days prior to screening.
5. History of unexplained recurrent infections, or use of systemic antibiotics within 90days prior to dosing.
6. Malignancy or history of malignancy, except non-melanoma skin cancer cured for morethan 3 years.
7. Positive HIV test (HIV-Ab), positive hepatitis B virus (HBV) test (HBsAg), positivehepatitis C virus (HCV), positive anti-syphilis helix-specific antibodies.
8. Participation in a clinical trial of any other drug within 3 months prior to screeningor within 5 half-lives of other clinical trial drugs (selecting the longer timeperiod).
9. Women who are pregnant, breastfeeding, or at risk of pregnancy.
10. Any condition deemed unsuitable for study participation by the investigator.